San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights
Excerpt
The two main classes of adjuvant hormonal therapy used in the treatment of postmenopausal women with hormone receptor–positive breast cancer are selective estrogen receptor modulators (for example, tamoxifen) and the aromatase inhibitors (AIs—for example, anastrozole, letrozole, exemestane). [...]
Share and Cite
Joy, A.A. San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights. Curr. Oncol. 2008, 15, 68-69. https://doi.org/10.3747/co.2008.203
Joy AA. San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights. Current Oncology. 2008; 15(1):68-69. https://doi.org/10.3747/co.2008.203
Chicago/Turabian StyleJoy, Anil A. 2008. "San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights" Current Oncology 15, no. 1: 68-69. https://doi.org/10.3747/co.2008.203
APA StyleJoy, A. A. (2008). San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights. Current Oncology, 15(1), 68-69. https://doi.org/10.3747/co.2008.203